Clinical Trial

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Study acronym: ATHENA
Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Protocol Amendment History 4 changes
critical Trial completed 2026-08-12
minor Trial arms changed: 4 -> 7 2026-08-12
notable Primary completion moved earlier: 2026-09-30 -> 2025-05-15 2026-08-12
minor Completion moved earlier: 2026-09-30 -> 2025-05-15 2026-08-12
Trial Details
NCT Number NCT04706923
Lead Sponsor SymBio Pharmaceuticals
Conditions Adenovirus Infections, Cytomegalovirus Infection
Enrollment 53 participants
Start Date 2021-08-16
Primary Completion 2025-05-15 (estimated)
Study Completion 2025-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-11